3557 results for «66+video+🫣🫣🫣🫣🫣🫣🫣»
3557 results
Learning from the Masters - Key learnings from 20 years of transcatheter edge-to-edge repair
15 May 2024 – From EuroPCR 2024
Maurizio Taramasso interviews Ottavio Alfieri, a pioneering figure in valve surgery and a key contributor to the development of transcatheter edge-to-edge repair, honored with the Ethica Award at the 2024 edition of #europcr. Ottavio Alfieri discusses his journey to becoming a cardiac surgeon, the genesis of...
How to recover a lost coronary implant or manage other embolised device complications?
15 May 2018
Embolised device complications
Embolised device complications can be classified in a variety of ways but are traditionally described either in relation to disease indication, the general phases of a procedure, or the use of specific devices. These types of complications can be life threatening, but if acting...
One year outcomes of transfemoral J-valve for chronic aortic regurgitation, a prospective multicenter study in 127 cases
20 May 2025 – From EuroPCR 2025
In this #europcr 2025 roundtable, Lai Wei and Dongming Hou present the latest data on the transfemoral J-Valve for chronic aortic regurgitation.
They begin with the China-DVD study, highlighting that aortic regurgitation is now slightly more prevalent than aortic stenosis in China. The conversation then shifts to...
Latest clinical evidence on intravascular lithotripsy from EuroPCR 2025
20 May 2025 – From EuroPCR 2025
In this #europcr 2025 roundtable, Niels Thue Olsen and Margaret McEntegart discuss with Flavio Luciano Ribichini the latest data on intravascular lithotripsy (IVL), based on two pivotal studies.
- EMPOWER CAD: the first prospective, real-world PCI trial dedicated to women with complex, calcified coronary artery disease. With an IVL-first strategy...
One-year results from the ADALA trial
16 Nov 2025 – From PCR London Valves 2025
Left atrial appendage (LAA) closure is a new focus at this year’s PCR London Valves Course, and, in this interview, Xavier Freixa and Christopher Allen discuss the ADALA trial and its impact on post-occlusion management.
The study compared three months of low-dose DOAC with three months of...
PARTNER 3 — 7-year follow-up: what it means for low-risk patients
16 Nov 2025 – From PCR London Valves 2025
Philippe Généreux and Philippe Pibarot discuss the long-term findings from PARTNER 3 and their practical implications for patient care.
They review the 7-year comparison of transfemoral TAVR versus surgical aortic-valve replacement in symptomatic patients with severe aortic stenosis who are at low surgical risk, and why the...
TARGET study interim results: safety and performance of Cardiovalve replacement system for tricuspid regurgitation
16 Nov 2025 – From PCR London Valves 2025
Georg Nickenig and Christopher Allen discuss transcatheter replacement for the tricuspid valve and a dedicated transfemoral device in this interview, focusing on the TARGET study.
TARGET set out to answer two questions: can tricuspid regurgitation (TR) be reduced to mild or zero, and what are the safety...
TAVI for aortic regurgitation in high surgical risk: outcomes in 700 patients from ALIGN-AR
16 Nov 2025 – From PCR London Valves 2025
Christopher Allen and Raj Makkar sit down to review the ALIGN-AR trial and its implications for treating native aortic regurgitation.
ALIGN-AR was a pivotal, single-arm, multicenter investigational study designed to evaluate a dedicated transcatheter solution in patients with moderate-to-severe native AR who were considered high risk for...
Hotline from EuroPCR 2025 - Five-year outcomes from the Evolut low risk TAVR bicuspid study
21 May 2025 – From EuroPCR 2025
Simon Redwood and John Forrest exchange insights on the Evolut Low Risk Bicuspid Study, which explores transcatheter aortic valve replacement (TAVR) in younger, low-risk patients with bicuspid aortic valves—an anatomy often excluded from earlier trials.
They review the trial design, patient characteristics, and results, comparing outcomes with...
What are the emerging indications for TAVI in 2025?
22 May 2025 – From EuroPCR 2025
Tiffany Patterson, Nicolas Van Mieghem, and Philippe Généreux discuss emerging indications for TAVI in 2025. They review recent evidence on asymptomatic severe aortic stenosis, highlighting four randomised trials—RECOVERY, AVATAR, ONLY TAVR, and EVoLVeD—that show TAVI or surgical AVR reduces hospitalisations for heart failure and trends toward...
Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome
21 May 2025 – From EuroPCR 2025
In this EuroPCR 2025 interview, Davide Capodanno and Woong Chol Kang discuss antithrombotic therapy in patients with acute coronary syndromes, focusing on the design and outcomes of the 4D-ACS trial. They describe the patient population enrolled in the study and introduce the two de-escalation strategies investigated:...
Benefits of IVUS plus near-infrared spectroscopy in detecting and managing vulnerable plaques
21 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Nilesh Pareek and Thomas Keeble discuss the clinical value and future potential of NIRS IVUS, a dual-modality imaging system developed by Nipro that combines intravascular ultrasound with near-infrared spectroscopy.
The Makoto™ system and Dualpro™ catheter allow real-time identification of lipid-rich plaques by providing both...
Learnings from Evolut Low Risk 5-year and SMART 2-year trials : from evidence to practice
21 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Angela McInerney, Didier Tchétché, and Ole De Backer discuss key results from the SMART and Evolut Low Risk trials. The SMART trial compared balloon-expandable and self-expanding valves in small annulus patients, showing better hemodynamics with the Evolut platform at 2 years. The Evolut...
Learnings from LANDMARK and Compare-TAVI at 3 years
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Andreas Baumbach, Christian Juhl Terkelsen and Didier Tchetche reviewed the latest findings from the LANDMARK and Compare-TAVI 1 trials—both focused on the performance of the Myval balloon-expandable valve.
LANDMARK compared Myval and Myval Octacor to leading self-expanding valves in a randomised controlled trial. At...
Focal or diffuse coronary disease: how can PPG measurement contribute to clinical decision-making?
22 May 2025 – From EuroPCR 2025
How can physiology guide treatment decisions beyond ischemia detection? In this round-table recorded at EuroPCR 2025, Thomas Engstrøm, Carlos Collet and Jeroen Sonck examine how pullback pressure gradient (PPG) makes it possible to identify the distribution pattern of coronary artery disease—focal or diffuse—based on a continuous...
How to successfully approach calcified bifurcation lesions?
20 May 2025 – From EuroPCR 2025
Calcified bifurcation lesions remain one of the toughest challenges in interventional cardiology, combining two high-risk features into one complex scenario.
In this discussion, Dejan Milasinovic, Miroslaw Ferenc, and Mohamed Abdel Wahab explain why this subset deserves dedicated attention. They highlight the critical role of intra-coronary imaging to...
How to successfully approach CTO interventions: a step-by-step approach
22 Oct 2025 – From EuroPCR 2025
Elliot Smith, Thomas Hovasse and Roberto Garbo discuss a comprehensive, step-by-step approach to CTO interventions, providing structured guidance on navigating CTOs in a safe and effective way.
The discussion begins with angiographic assessment, emphasising the importance of identifying key anatomical features upfront. Based on this evaluation, operators determine...
Tricuspid TEER: learnings from the 2-year outcomes of TRILUMINATE Pivotal trial & bRIGHT study
20 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Marianna Adamo and Ralph Stephan von Bardeleben discussed the latest findings on tricuspid valve repair using transcatheter edge-to-edge repair (TEER).
The 2-year results from the TRILUMINATE Pivotal trial showed a significant reduction in tricuspid regurgitation, lasting improvements in quality of life, and a notable...
Early treatment of severe aortic stenosis: do we need to wait?
20 May 2025 – From EuroPCR 2025
Rahul Sharma and Darren Walters share their perspectives on shifting treatment strategies for aortic stenosis (AS), with a focus on early intervention.
Their conversation draws on the EARLY TAVR trial, which compared transcatheter aortic valve replacement (TAVR) to clinical surveillance in patients with severe, asymptomatic AS at low surgical...
Are we undertreating aortic regurgitation?
20 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Victoria Delgado, Helge Möllmann, and Dan Blackman gather to discuss a crucial but often under-addressed challenge in structural heart disease: the under-referral and under-treatment of patients with aortic regurgitation (AR).
The conversation begins with the diagnostic challenges surrounding severe AR, followed by a striking observation—only...
